CL2007002240A1 - Compuestos derivados de iminoimidazopiridina; procedimiento de preparacion; y uso para la profilaxis, prevencion secundaria y terapia de infarto de miocardio, accidentes cerebrovasculares y trastornos vasculares perifericos entre otros. - Google Patents

Compuestos derivados de iminoimidazopiridina; procedimiento de preparacion; y uso para la profilaxis, prevencion secundaria y terapia de infarto de miocardio, accidentes cerebrovasculares y trastornos vasculares perifericos entre otros.

Info

Publication number
CL2007002240A1
CL2007002240A1 CL200702240A CL2007002240A CL2007002240A1 CL 2007002240 A1 CL2007002240 A1 CL 2007002240A1 CL 200702240 A CL200702240 A CL 200702240A CL 2007002240 A CL2007002240 A CL 2007002240A CL 2007002240 A1 CL2007002240 A1 CL 2007002240A1
Authority
CL
Chile
Prior art keywords
infarts
iminoimidazopiridine
profilaxis
myocardium
therapy
Prior art date
Application number
CL200702240A
Other languages
English (en)
Inventor
Uwe Hofmeister Armin L Heinelt
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2007002240A1 publication Critical patent/CL2007002240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CL200702240A 2006-08-02 2007-08-01 Compuestos derivados de iminoimidazopiridina; procedimiento de preparacion; y uso para la profilaxis, prevencion secundaria y terapia de infarto de miocardio, accidentes cerebrovasculares y trastornos vasculares perifericos entre otros. CL2007002240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006036023A DE102006036023A1 (de) 2006-08-02 2006-08-02 Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität

Publications (1)

Publication Number Publication Date
CL2007002240A1 true CL2007002240A1 (es) 2008-02-08

Family

ID=38884850

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702240A CL2007002240A1 (es) 2006-08-02 2007-08-01 Compuestos derivados de iminoimidazopiridina; procedimiento de preparacion; y uso para la profilaxis, prevencion secundaria y terapia de infarto de miocardio, accidentes cerebrovasculares y trastornos vasculares perifericos entre otros.

Country Status (24)

Country Link
US (1) US7863269B2 (es)
EP (1) EP2054412B1 (es)
JP (1) JP5149897B2 (es)
KR (1) KR20090129981A (es)
CN (1) CN101495478B (es)
AR (1) AR062158A1 (es)
AT (1) ATE450537T1 (es)
AU (1) AU2007280780B2 (es)
BR (1) BRPI0714599A2 (es)
CA (1) CA2663332C (es)
CL (1) CL2007002240A1 (es)
DE (2) DE102006036023A1 (es)
DK (1) DK2054412T3 (es)
DO (1) DOP2007000120A (es)
ES (1) ES2336044T3 (es)
HK (1) HK1135694A1 (es)
IL (1) IL196789A (es)
MX (1) MX2009000408A (es)
MY (1) MY148611A (es)
NO (1) NO20090741L (es)
PE (1) PE20080687A1 (es)
PT (1) PT2054412E (es)
TW (1) TWI400240B (es)
WO (1) WO2008014888A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008490A (es) * 2008-02-05 2010-08-18 Sanofi Aventis Triazolopiridazinas como inhibidores de par1, su produccion y su uso como medicamentos.
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (es) * 1971-03-15 1976-07-24
DE2221796A1 (de) 1972-05-04 1973-11-15 Kraemer Kg Wilhelm Batteriebehaelter fuer stabbatterien
JPS60161986A (ja) * 1983-12-24 1985-08-23 Nippon Soda Co Ltd イミダゾ（１，５−ａ）ピリジン−３−オン誘導体及びその製造方法
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040242627A1 (en) * 2001-04-19 2004-12-02 Shuichi Suzuki 2-Iminoimidazole derivatives (1)
ATE494284T1 (de) 2002-04-16 2011-01-15 Schering Corp Tricyclischer thrombinrezeptorantagonist
AU2004218187C1 (en) 2003-02-19 2011-04-07 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
US7317124B2 (en) * 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
DE10353205A1 (de) 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen

Also Published As

Publication number Publication date
NO20090741L (no) 2009-02-16
TW200821308A (en) 2008-05-16
CA2663332C (en) 2015-06-02
EP2054412A2 (de) 2009-05-06
IL196789A (en) 2012-07-31
ATE450537T1 (de) 2009-12-15
DOP2007000120A (es) 2008-02-29
MY148611A (en) 2013-05-15
US7863269B2 (en) 2011-01-04
KR20090129981A (ko) 2009-12-17
CN101495478A (zh) 2009-07-29
IL196789A0 (en) 2009-11-18
DE502007002219D1 (de) 2010-01-14
WO2008014888A2 (de) 2008-02-07
WO2008014888A3 (de) 2008-06-12
DE102006036023A1 (de) 2008-02-07
CA2663332A1 (en) 2008-02-07
PT2054412E (pt) 2010-02-04
BRPI0714599A2 (pt) 2013-04-09
AR062158A1 (es) 2008-10-22
AU2007280780A1 (en) 2008-02-07
DK2054412T3 (da) 2010-04-19
JP2009545542A (ja) 2009-12-24
HK1135694A1 (en) 2010-06-11
ES2336044T3 (es) 2010-04-07
EP2054412B1 (de) 2009-12-02
AU2007280780B2 (en) 2012-03-29
CN101495478B (zh) 2013-03-27
JP5149897B2 (ja) 2013-02-20
PE20080687A1 (es) 2008-07-24
US20090192150A1 (en) 2009-07-30
TWI400240B (zh) 2013-07-01
MX2009000408A (es) 2009-01-27

Similar Documents

Publication Publication Date Title
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2012001762A1 (es) Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
BRPI0615163A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.